The Exact Language That Gets Insurance Denials Overturned

Most insurance appeal letters fail before the reviewer reads the second paragraph. Not because the clinical case is weak, but because the letter doesn't engage with the denial on the insurer's own terms.

An appeal letter that restates the original request — "my doctor prescribed this medication and it is medically necessary" — gives the reviewer nothing to work with. The insurer already reviewed that request and denied it. A letter that explains why the denial criteria were not correctly applied, and provides evidence that specifically addresses those criteria, is a different kind of document. It forces a substantive response.

Understanding what separates those two kinds of letters is the difference between an appeal that goes nowhere and one that actually gets overturned.

Why Most Appeals Fail

According to a 2024 survey by the American Medical Association, prior authorization denials are overwhelmingly appealed at low rates — the AMA has consistently found that the administrative burden of appealing keeps most patients and physicians from doing so. When appeals are filed, the success rates vary significantly by plan type, condition, and how the appeal is constructed.

The most common failure mode is not insufficient clinical evidence. It is evidence that doesn't respond to the specific denial reason.

Insurance plans deny claims under specific criteria drawn from their coverage policies. "Not medically necessary" is not a generic finding — it reflects a clinical review against a specific standard. "Step therapy not completed" reflects a specific sequence the plan requires. When your appeal letter doesn't engage with those specific standards, it reads as a resubmission, not a rebuttal.

A successful appeal requires three things: the denial reason in the insurer's own language, clinical evidence that addresses that specific reason, and documentation tying the medical necessity to your individual case. All three. Not one, not two.

Start With the Denial Letter, Not the Prescription

Before writing a single sentence of your appeal, read the denial letter carefully and identify the exact reason given. Pull the language verbatim. This is the framework your appeal must respond to.

Your insurer is legally required to provide you with the specific reason for the denial and the criteria used to make the determination. If the denial letter is vague, you can request the full clinical criteria document — the actual coverage policy that was applied. That document tells you exactly what the reviewer was checking for when they denied your claim. Your appeal should speak to every item on that list.

The AMA recommends that appeal letters open by acknowledging the denial decision and citing the plan's own criteria — not to agree with the denial, but to demonstrate that the appeal is a direct response to it, not a new submission.

The Language That Works for Common Denial Types

"Not Medically Necessary"

This is the most common denial reason, and the most often successfully appealed. It means the reviewer concluded that the requested drug does not meet the plan's standard for medical necessity for your diagnosis and clinical situation.

To overturn it, your appeal must demonstrate that clinical guidelines from recognized professional societies support the use of this drug for your condition, at this stage of disease, for patients with your clinical history.

Effective language cites those guidelines directly: "According to the [American College of Rheumatology / National Comprehensive Cancer Network / American Academy of Dermatology] clinical practice guidelines for [condition], [drug name] is a recommended treatment for patients with [specific criteria that apply to this case]." Then document how the patient meets those criteria.

The citation must be to the specific guideline, not the drug manufacturer's website. Payer clinical reviewers weight society guidelines heavily. For oncology, NCCN guidelines carry particular authority. For rheumatologic conditions, ACR guidelines. For dermatology, AAD. Using the specific guideline the payer's own clinical criteria reference — often cited in the coverage policy document you requested — is more effective than a general statement of clinical appropriateness.

"Step Therapy Not Completed"

Step therapy denials mean the plan requires you to try a less expensive drug before approving the one your physician prescribed. The appeal has two pathways: demonstrate that step therapy was already completed, or demonstrate that you qualify for a medical exception.

If you already tried the required drug, the appeal must document the trial with specificity: dates of treatment, doses, duration, and the clinical outcomes that led your physician to discontinue. An appeal that says "the patient tried drug X and it did not work" will be weaker than one that says "the patient was treated with [drug] at [dose] from [date] to [date], resulting in [specific clinical outcomes — e.g., inadequate disease control per [measure], documented adverse effect of [specific effect], or treatment failure confirmed by [lab, imaging, or clinical assessment]." Specificity is the difference.

If you have not tried the required drug but have a medical reason you cannot, the appeal must document that contraindication or medical exception. Acceptable reasons vary by plan and condition, but they typically include documented intolerance or prior adverse reaction, a contraindication based on another medical condition, disease severity that makes a trial of the step drug clinically inappropriate, or prior authorization of the same drug under a different insurer. Your physician's letter should address the specific exception criteria the plan's coverage policy allows.

Many states have enacted step therapy reform laws that define the circumstances under which plans must grant exceptions. The National Conference of State Legislatures maintains a database of state step therapy laws. If your state has such a law, cite it explicitly in your appeal.

"Experimental or Investigational"

This denial applies when a plan's clinical reviewers determine that the evidence base for a drug does not meet their standard for established efficacy. It is most commonly applied to off-label uses, drugs awaiting full FDA approval, or treatments where the plan's policy lags peer-reviewed evidence.

The appeal requires the same kind of documented clinical evidence, but focused on establishing the evidence base itself: the FDA approval status and indication, peer-reviewed clinical trials supporting the use, clinical society guidelines that include the drug in their recommendations, and, when available, the payer's own coverage policy on the condition to show that the use requested falls within or near covered indications.

If the drug has FDA approval for the specific indication requested, state that clearly at the top of the appeal. An experimental denial against an FDA-approved use is an administrative error, and reviewers will generally overturn it when the approval documentation is provided.

"Quantity Limit Exceeded"

Quantity limit denials apply when the requested dose or frequency exceeds the plan's standard parameters for a drug. The appeal requires clinical guidelines that support the requested quantity, documentation of the clinical rationale specific to this patient, and, when appropriate, peer-reviewed literature supporting higher dosing in certain patient populations.

If the prescribing physician has documented a specific clinical reason for the quantity requested — body weight, disease severity, clinical response to lower doses — that documentation should be included verbatim in the appeal, not summarized.

The Peer-to-Peer Review

If your written appeal is denied at the internal level, or if you need an expedited resolution, request a peer-to-peer review. This is a direct phone call between your prescribing physician and the insurer's medical director or clinical reviewer who made the denial decision.

The AMA recommends peer-to-peer reviews as one of the most effective tools for overturning denials because they move the conversation from documentation to dialogue. A clinical reviewer who might uphold a denial on paper will sometimes reverse it in a direct conversation with a treating specialist who can address specific clinical nuances the file doesn't capture.

Not every insurer makes peer-to-peer calls easy to schedule. Your physician's office will need to initiate the request, and timing matters — most plans have a limited window in which a peer-to-peer can be requested relative to the denial date. Confirm the deadline with the insurer as soon as possible.

The physician preparing for a peer-to-peer call should expect to speak directly to the denial criteria, not simply advocate for the patient. The most effective calls are the ones where the treating physician can speak precisely to why the denial criteria were not met — the same framework the written appeal uses.

External Independent Review

If your internal appeal is denied, federal law under the Affordable Care Act gives you the right to request an external independent review for most commercial insurance plans and ACA marketplace plans. External review is conducted by an independent organization, not the insurer, and the insurer is required to comply with the outcome.

External review outcomes consistently favor patients at significant rates in certain categories. According to KFF analysis of state external review data, overturn rates in some states and plan types run well above 40%. This is not a last resort. For many patients, it is where the real leverage is.

The external review request must typically be filed within a specific window after the internal appeal denial. Check your Explanation of Benefits and denial letter for the exact deadline.

When to Use This Framework

This framework applies whether you are filing the appeal yourself, asking your physician's office to file on your behalf, or working with a patient advocate. The structure is the same in every case: start with the insurer's denial language, respond to each criterion directly, cite clinical evidence that meets those criteria, and document the individual clinical facts that establish medical necessity for this patient.

Ellen builds appeal letters using this framework automatically, tailored to your specific insurer and denial reason. Start at ellenrx.com.

Sources: American Medical Association, "2024 Prior Authorization Physician Survey"; Kaiser Family Foundation, "Consumer Protections in Appeals and External Review," 2023; National Conference of State Legislatures, "Step Therapy/Fail First Policies," 2024; American College of Rheumatology, ACR Guidelines library; National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology; American Academy of Dermatology, AAD clinical practice guidelines; U.S. Department of Labor, "External Claims Appeal," ACA summary.